Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME
January 11, 2021 at 01:00 pm
Adverum Biotechnologies, Inc. announced the completion of patient enrollment in the INFINITY Phase 2 trial to evaluate a single intravitreal injection of ADVM-022, for the treatment of diabetic macular edema (DME). The company will provide a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021 at 10:50 a.m. ET. The live webcast will be accessible under Events and Presentations in the Investors section of the company's website.